Recent Updates
Recently added Catalysts

CTI-1601

Phase 2

Friedreich Ataxia | Monoclonal antibody | Rare Disease |Larimar Therapeutics, Inc.|Last Updated: Sep 3, 2026

Target and mechanism

Molecular targetFXN
ModalityMonoclonal antibody

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials4
Total Enrollment168

FDA Designations

ORPHAN_DRUGRARE_PEDIATRIC_DISEASEFAST_TRACK

Clinical trial landscape

CTI-1601 · 4 trials · 1 indication

Phase 2 2Phase 1 2
NCT06447025An Open-Label Study of CTI-1601 in Subjects With Friedreich's AtaxiaFriedreich Ataxia
RECRUITING85 Analytics
NCT05579691A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's AtaxiaFriedreich Ataxia
COMPLETED28 Analytics
PHASE2RECRUITING
An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
Friedreich AtaxiaUnlock trial analytics
PHASE2COMPLETED
A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia
Friedreich AtaxiaUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of subjects with treatment-emergent adverse events (TEAEs) by System Organ Class (SOC), Preferred Term (PT) and Maximum Severity
Up to 24 months

Number of subjects

Change from baseline in electrocardiogram (ECG) parameters including, but not limited to, HR, RR interval, PR interval, QRS duration, QT interval, and QTcF interval
Up to 24 months

Number change in ECG parameters

Change from baseline in left ventricular ejection fraction (LVEF)
Up to 24 months

LVEF indicates the percentage of change in LV volume from diastole to systole that measures how well the left ventricle of the heart pumps blood.

Change from baseline in left ventricular end-diastolic volume (LVEDV)
Up to 24 months

LVEDV is the amount of blood, measured in milliliters (mL), in the heart's left ventricle just before the heart contracts.

Number of subjects with any suicidal ideation or behavior (Categories 1-10) of the Columbia Suicide Severity Rating Scale (C-SSRS)
Up to 24 months

The Columbia Suicide Severity Rating Scale (C-SSRS) is a tool used to assess the occurrence, severity, and frequency of suicidal thoughts and behaviors. A higher score on the C-SSRS generally indicate a worse outcome, as they signify a higher level of suicidal ideation or behavior.

Change from baseline at each collection timepoint in tissue frataxin concentrations normalized to total protein observed in buccal cells collected from cheek swabs and skin cells collected from skin punch biopsies
Up to 24 months
Change from baseline in motor function as assessed by 9-hole peg test (9-HPT)
Up to 24 months
Change from baseline in motor function as assessed by the timed 25-foot walk test (T25-FW)
Up to 24 months
Change from baseline in neurologic function as assessed by the modified Friedreich's Ataxia Rating Scale (mFARS) total score
Up to 24 months

The Modified Friedreich's Ataxia Rating Scale (mFARS) is a modified neurologic scale involving direct subject participation and targets specific areas impacted by Friedreich's ataxia (bulbar, upper limb, lower limb, and upright stability), with scores ranging from 0-67 points, with higher scores indicating a greater level of disability.

Change from baseline in neurologic function as assessed by the upright stability subscale examination of the mFARS
Through study completion, up to 24 months

The Upright Stability Subscale is an assessment of an individual's ability to maintain balance and stability while standing upright. It has a minimum value of 0 and a maximum value of 36. A higher score indicates a better outcome, reflecting greater stability and balance abilities while standing upright.

Change in activities of daily living (ADLs) as assessed by the Friedreich's Ataxia Rating Scale Activities of Daily Living (FARS_ADL)
Up to 24 months

The FARS\_ADL, scored 0 to 36, is a subscale of FARS assessing a subject's ability to complete activities of daily living. A higher score indicates a greater level of disability. The FARS\_ADL questionnaire will be performed at the timepoints indicated in protocol.

Change from baseline in total fatigue score and all the subscale scores as assessed by the Fatigue Impact Scale (MFIS)
Up to 24 months

The Modified Fatigue Impact Scale (MFIS) is a revised form of the Fatigue Impact Scale based on items derived from interviews with MS patients concerning how fatigue impacts their lives. This instrument provides an assessment of the effects of fatigue in terms of physical, cognitive, and psychosocial functioning. Participants rate on a 5-point scale, with 0 = 'Never' to 4 = 'Almost always' their agreement with 21 statements. Total score (0-84) and subscales for physical (0-36), cognitive (0-40) and psychosocial functioning (0-8). The 5-item version is scored (0-20). Higher numbers indicate greater fatigue. The MFIS will be performed at the timepoints indicated in protocol.

Change from baseline in the assessment of disease as assessed by the Functional Staging for Ataxia
Up to 24 months
Overall impression of change as assessed by the patient using the Patient Global Impression of Change (PGI-C) Scale
Up to 24 months

The Patient Global Impression of Change (PGI-C) reflects a patient's assessment about the efficacy of treatment. PGIC is a 7 point scale depicting a patient's rating of overall improvement. Patients rate their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse." The PGI-C will be performed at the timepoints indicated in protocol.

Overall impression of change assessed by a clinician using the Clinical Global Impression of Change (CGI-C)
Up to 24 months

The Clinical Global Impression of Change (CGI-C) is an assessment to measure change in clinical status (symptoms and functional ability) of the subject's condition from baseline with study drug. CGI-C scores range from 1 (very much improved) through to 7 (very much worse). The CGI-C will be performed at the timepoints indicated in protocol.

Area under the concentration-time curve for the dosing interval (AUC0-tau)
Days 1, 30, 60, 90: pre-dose, 5, 15, 30 minutes after the dose, and 1, 2, 4, 6, 8 hours after the dose; Day 180: pre-dose and 5, 15 minutes after the dose; Days 270, 360, Q3M thereafter: pre-dose; through study completion, up to 24 months
Area under the concentration-time curve from time 0 to the time of last quantifiable concentration (AUC0-t)
Days 1, 30, 60, 90: pre-dose, 5, 15, 30 minutes after the dose, and 1, 2, 4, 6, 8 hours after the dose; Day 180: pre-dose and 5, 15 minutes after the dose; Days 270, 360, Q3M thereafter: pre-dose; through study completion, up to 24 months
Mean maximum observed concentration (Cmax)
Days 1, 30, 60, 90: pre-dose, 5, 15, 30 minutes after the dose, and 1, 2, 4, 6, 8 hours after the dose; Day 180: pre-dose and 5, 15 minutes after the dose; Days 270, 360, Q3M thereafter: pre-dose; through study completion, up to 24 months
Mean time of maximum observed concentration (Tmax)
Days 1, 30, 60, 90: pre-dose, 5, 15, 30 minutes after the dose, and 1, 2, 4, 6, 8 hours after the dose; Day 180: pre-dose and 5, 15 minutes after the dose; Days 270, 360, Q3M thereafter: pre-dose; through study completion, up to 24 months
Concentration reached immediately before the next dose is administered (Ctrough)
Days 1, 30, 60, 90: pre-dose, 5, 15, 30 minutes after the dose, and 1, 2, 4, 6, 8 hours after the dose; Day 180: pre-dose and 5, 15 minutes after the dose; Days 270, 360, Q3M thereafter: pre-dose; through study completion, up to 24 months
Number of Participants with Treatment Emergent Adverse Events
Through study completion, an average of 93 days

Overall summary of Participants with Treatment Emergent Adverse Events

Number of Participants with Treatment Emergent Adverse Events by System Organ Classification and Preferred Term
Through study completion, an average of 75 days

Overall summary of Participants with Treatment Emergent Adverse Events by System Organ Classification (MedDRA version 23.0)

Number of Participants with Treatment-Emergent Adverse Events
Through study completion, an average of 70 days

Overall summary of the Participants with Treatment Emergent Adverse Events

Number of Treatment Emergent Adverse Events by System Organ Classification and Preferred Term
Through study completion, an average of 70 days

Overall summary of Participants with Treatment Emergent Adverse Events by System Organ Classification (MedDRA version 22.0)

Secondary Endpoints

Maximum observed plasma concentration (Cmax) of CTI-1601 after multiple doses
At baseline and up to 29 days
Area under the concentration time curve (AUC) of CTI-1601 from time 0 through the last measurable time point
At baseline and up to 29 days
Time to maximum observed plasma concentration (tmax) of CTI-1601 after multiple doses
At baseline and up to 29 days
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
CTI-1601EXPERIMENTALOnce daily subcutaneous injection of 50 mg CTI-1601 in subjects ≥ 18 years of age or a weight-based dose of 0.8 mg/kg up to a maximum of 50 mg in subjects ≥ 2 to 17 years of age.
CTI-160lEXPERIMENTALCTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
PlaceboPLACEBO_COMPARATORPlacebo Comparator

Interventions

NameTypeDescription
CTI-1601DRUGCTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in patients with Friedreich's ataxia
PlaceboOTHERPlacebo Comparator
Unlock Study Design Details

Eligibility Criteria

Age Range2 Years to 60 Years
SexALL
Healthy VolunteersNo
Study Sites8

Inclusion Criteria: * Subjects with FRDA who have or have not previously completed participation in a study of CTI-1601 are eligible to participate in this study unless the subject experienced one or more of the following in a previous CTI-1601 study: a) serious adverse event (SAE) related to study...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWSep 3, 2026NCT06447025lastUpdatePostDate: changed
LOWSep 3, 2026NCT06447025lastUpdatePostDate: changed

Frequently asked questions about CTI-1601

What is CTI-1601 used for?

CTI-1601 is an investigational therapy being developed for Friedreich Ataxia, a rare inherited disease that affects the nervous system and heart. It is currently in Phase 2 clinical development and has not been approved by the FDA.

What does CTI-1601 target?

CTI-1601 targets FXN, the protein that is deficient in Friedreich Ataxia. It is a monoclonal antibody designed to address the underlying cause of the disease by targeting this specific protein.

Who makes CTI-1601?

CTI-1601 is being developed by Larimar Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol LRMR.

What phase is CTI-1601 in?

CTI-1601 is currently in Phase 2 clinical development. It has completed Phase 1 and Phase 2 trials and is now being studied in an open-label Phase 2 trial. It is investigational and not yet FDA approved.

What clinical trials is CTI-1601 in?

CTI-1601 has been studied in four clinical trials. Completed trials include NCT04176991, NCT04519567, and NCT05579691. The ongoing trial is NCT06447025, an open-label Phase 2 study in Friedreich Ataxia patients aged 2 years and older.

Is CTI-1601 the same as any other drug?

CTI-1601 is the primary name for this investigational therapy. No alternative names have been reported for this drug in clinical trial records.